

Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Brenda Weigel, M.D.**

Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Meeting Date: June 22, 2017

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: On June 22, 2017, information will be presented to gauge investigator interest in exploring potential pediatric development plans for two products in various stages of development for adult cancer indications. The subcommittee will consider and discuss issues concerning diseases to be studied, patient populations to be included, and possible study designs in the development of these products for pediatric use. The discussion will also provide information to the Agency pertinent to the formulation of written requests for pediatric studies, if appropriate. The products under consideration are: (1) Olaratumab, application sponsored by Eli Lilly and Company; and (2) Prexasertib, application sponsored by Dista Products/Eli Lilly and Company, I may be considered for participation in the advisory committee meeting described above.

I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
None		
<b>II. Other Imputed Interests</b>		
Contracts/grants	Three interests with Eli Lilly, sponsor	\$0 - \$50,000 total, per interest

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/  
Signature

\_\_\_\_\_**06/02/2017**  
Date